[go: up one dir, main page]

EP4619008A1 - Solution d'hypochlorite pour le traitement de tissu cicatriciel - Google Patents

Solution d'hypochlorite pour le traitement de tissu cicatriciel

Info

Publication number
EP4619008A1
EP4619008A1 EP23809512.9A EP23809512A EP4619008A1 EP 4619008 A1 EP4619008 A1 EP 4619008A1 EP 23809512 A EP23809512 A EP 23809512A EP 4619008 A1 EP4619008 A1 EP 4619008A1
Authority
EP
European Patent Office
Prior art keywords
hypochlorite solution
hypochlorite
optionally
solution
scar tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23809512.9A
Other languages
German (de)
English (en)
Inventor
Myles DAKIN
Richard Aspinall
Thomas Kenny
Christopher Chapman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hypo Stream Ltd
Original Assignee
Hypo Stream Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypo Stream Ltd filed Critical Hypo Stream Ltd
Publication of EP4619008A1 publication Critical patent/EP4619008A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Definitions

  • the present invention relates to a hypochlorite solution for the prophylactic treatment of, or treatment of, scar tissue in a mammal.
  • Scar tissue is a fibrous tissue that forms following trauma to the skin as part of the healing process, or as a result of particular diseases or conditions. Scar tissue is typically formed of collagen and has several differences compared to normal healthy tissue. For instance, scar tissue on the surface of the skin may be characterised by one or more of a raised profile, discoloration, increased sensitivity to sunlight, tightness/reduced elasticity, an absence of sweat glands, and an absence of hair follicles, as compared to normal skin tissue surrounding the scar. Scar tissue may also form internally within the body following major trauma (e.g. internal scars following surgery).
  • Scar tissue is typically less flexible than normal tissue because the collagen proteins formed during the healing process typically form in a unidirectional manner. This causes a reduction in tissue elasticity, which may result in recurring pain for a patient and/or restrictions to their normal range of motion. From a cosmetic point of view, scar tissue on the surface of the skin is generally considered to be unsightly.
  • the current standard of care is to treat scar tissue that has already formed.
  • Existing treatments are not suitable for treating open wounds or wounds early in the stage of the healing process, with a view to mitigating or reducing the formation of scar tissue in the first instance.
  • There are limited treatments available for reducing or mitigating the formation of scar tissue during the healing process or at an early stage of the healing process e.g. treatment of an open wound.
  • Sodium hypochlorite solutions have been used for the purposes of wound irrigation to disinfect a wound.
  • Such solutions include Dakin’s solution which has been used as an antiseptic, and typically comprises 0.4-0.5% sodium hypochlorite and buffering agents to provide a pH of 9-10.
  • Modified forms of Dakin’s solution have been prepared as antibacterial solutions to disinfect wounds.
  • GB2519774 and GB2527264 describe a hypochlorite solution for use in prevention or treatment of an inflammatory response in uncontaminated or non-infected surgical sites, wounds, trauma sites, internal inflammatory lesions or surface inflammatory lesions where there is no infection.
  • the hypochlorite solution described therein may comprise sodium hypochlorite in a concentration range of 0.005-0.2 wt% and may further comprise sodium chloride in a concentration range of 0.5-1.5 wt%.
  • Inflammatory conditions such as mouth ulcers, eczema and psoriasis are mentioned, and the treatment of the inflammatory response in an open fistula is exemplified.
  • GB2519774 nor GB2527264 contemplate use of the hypochlorite solution described therein for purposes other than mitigating the inflammation response, and do not contemplate prophylaxis of scar tissue.
  • the inventors have surprisingly discovered that treating wounds with a hypochlorite solution comprising 0.01-0.2 wt% (about 100-2000 ppm by wt; e.g. about 0.015-0.06 wt% [about 150-600 ppm by wt]) is effective in the prophylactic treatment of scar tissue. Indeed, more particularly the inventors have discovered that by applying the hypochlorite solution described herein to new or recent wounds (that is to say wounds less than 10 days old), scar tissue formation can be dramatically reduced or even avoided. The inventors have further found that application of the hypochlorite solution leads to improved overall appearance of the wound area, and minimises the extent of the scar tissue.
  • hypochlorite solution for use as described herein leads to formation of normal healthy tissue where scar tissue may normally be expected.
  • the inventors postulate that this formation of normal healthy tissue is promoted by the unexpected and unpredictable effects of the hypochlorite solution described herein on cytokines involved in scar tissue formation.
  • a hypochlorite solution for use in the prophylactic treatment of scar tissue in a mammal, preferably a human, wherein the hypochlorite solution comprises hypochlorite in a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt; e.g. about 0.015-0.06 wt% [about 150-600 ppm by wt]).
  • the hypochlorite concentrations modulate cytokines involved in the formation of scar tissue, and promote activity of cytokines linked to reducing scar formation. More particularly, the inventors have found that the hypochlorite solution described herein promotes interleukin (IL-10) activity, which is associated with reduced scar tissue formation. The inventors further demonstrate that the claimed solutions achieve reduction in scar formation in the clinic (see examples).
  • IL-10 interleukin
  • the prophylactic treatment may comprise, or consist of, topical administration of the hypochlorite solution to a mammal, preferably a human, in need thereof. More particularly, the administration of the hypochlorite solution may comprise topical administration of the hypochlorite solution to a particular area of a mammal, preferably a human, in need thereof where the particular area is a site of trauma, or a site of a disease or condition characterised by the abnormal formation of collagen.
  • the prophylactic treatment may comprise topical administration of the hypochlorite solution to a wound or site of trauma (e.g. trauma from surgery).
  • the prophylactic treatment may comprise administration of the hypochlorite solution to a wound, optionally wherein the wound is a trauma site or a surgical wound.
  • the scar tissue to be prophylactically treated may be scar tissue from healing of a wound, optionally wherein the wound is a trauma site or a surgical wound.
  • the wound may be sutured or may be an open wound.
  • the hypochlorite solution described herein is particularly effective in prophylactic treatment of open wounds, e.g. open wounds that have not yet closed by natural healing processes.
  • the prophylactic treatment may comprise administration of the hypochlorite solution to the wound during the period in which the wound is healing.
  • the wound On the first day of administration of the hypochlorite solution to the wound, the wound is optionally less than 10 days old, optionally less than 5 days old, optionally still less than 1 day old.
  • the wound On the first day of administration of the hypochlorite solution, the wound may be less than 24 hours old, optionally less than 12 hours old, and optionally less than 6 hours old.
  • the hypochlorite solution is administered to the wound immediately when the wound is fresh (i.e. within 1 hour or within 2 hours or within 3 hours of the wound being inflicted).
  • the prophylactic treatment may comprise administration of the hypochlorite solution to the wound by topical administration.
  • the scar tissue may be selected from one or more of keloid scar tissue, hypertrophic scar tissue, and scar contractures.
  • the scar tissue to be prophylactically treated may be scar tissue caused by a disease or condition that is characterised by the abnormal production of collagen.
  • Diseases or conditions characterised by the abnormal production of collagen may be referred to as collagen diseases or collagen conditions.
  • Collagen diseases or conditions may be selected from the list including myocardial fibrosis and purpura fulminans.
  • Collagen disease or conditions may be selected from pulmonary fibrosis, chronic obstructive pulmonary disease, and long COVID-19.
  • the mammal may have been identified as being at risk of developing a lung disease or lung condition which causes scarring of the lungs, optionally wherein the lung disease or lung condition is selected from pulmonary fibrosis, chronic obstructive pulmonary disease, and long COVID-19.
  • the mammal may have been identified as being at risk of developing long COVID-19 following a positive diagnosis of COVID-19 infection.
  • the prophylactic treatment may comprise administration of the hypochlorite solution to the lungs via inhalation.
  • the collagen disease or condition is not a respiratory condition or disease.
  • the collagen disease or condition is not a respiratory condition or disease selected from acute respiratory distress syndrome (ARDS); asthma; bronchitis; chronic obstructive pulmonary disease (COPD); common cold; coronaviral diseases such as severe acute respiratory syndrome (SARS), COVID-19; cystic fibrosis; influenza; Middle East respiratory syndrome (MERS); pneumonia, such as viral pneumonia, bacterial pneumonia and ventilator-associated pneumonia; pulmonary fibrosis; rhinoviral diseases; sarcoidosis (e.g. affecting lungs); tuberculosis; or inflammation of lung tissue.
  • ARDS acute respiratory distress syndrome
  • COPD chronic obstructive pulmonary disease
  • COVID-19 cystic fibrosis
  • influenza Middle East respiratory syndrome
  • MERS Middle East respiratory syndrome
  • pneumonia such as viral pneumonia, bacterial pneumonia and ventilator-associated pneumonia
  • pulmonary fibrosis pulmonary fibrosis
  • rhinoviral diseases sarcoidosis (e.g
  • the prophylactic treatment may comprise administration of the hypochlorite solution to the mammal on consecutive days.
  • the administration of the hypochlorite solution may be for at least 2 consecutive days, optionally for at least 3 consecutive days, optionally at least 4 consecutive days, optionally at least 5 consecutive days, optionally at least 6 consecutive days, and optionally at least 7 consecutive days.
  • the administration of the hypochlorite solution may be for at least 14 consecutive days, optionally at least 21 consecutive days, further optionally at least 30 consecutive days.
  • the treatment may comprise administration of the hypochlorite solution on alternate days, for a period of at least 7 days, optionally at least 14 days, optionally at least 28 days.
  • the prophylactic treatment may comprise administration of the hypochlorite solution to the mammal at least once daily.
  • the prophylactic treatment may comprise administration of the hypochlorite solution to the mammal at least twice daily (e.g. twice daily or three times daily).
  • the prophylactic treatment may comprise administration of the hypochlorite solution to the mammal at least three-times daily (e.g. three times daily or four times daily).
  • the prophylactic treatment may comprise administration of the hypochlorite solution to the mammal at least four times daily (e.g. four times daily or fives time daily).
  • the prophylactic treatment may comprise administration of the hypochlorite solution to the mammal at least five times daily (e.g. five time daily or six times daily).
  • the hypochlorite solution may comprise hypochlorite in a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt), wherein the hypochlorite is sodium hypochlorite.
  • the hypochlorite solution may comprise hypochlorite in a concentration range of about 0.01-0.1 wt% (about 100-1000 ppm by wt), more preferably about 0.015-0.075 wt% (about 150-750 ppm, even more preferably about 0.025-0.075 wt% (about 250-750 ppm by wt), most preferably about 0.04-0.06 wt% (about 400-600 ppm by wt).
  • the hypochlorite concentration may be 0.045-0.055 wt%, for example 0.05 wt% (500 ppm).
  • the hypochlorite solution may comprise hypochlorite in a concentration range of about 0.0175-0.065 wt% (about 175-650 ppm), for instance about 0.02-0.06 wt% (about 200- 600 ppm [e.g. about 200-500 ppm]).
  • the hypochlorite solution may comprise hypochlorite in a concentration range of about 0.015-0.06 wt% (about 150-600 ppm by wt), optionally about 0.02-0.055 wt% (about 200- 550 ppm), optionally still about 0.02-0.05 wt% (about 200-500 ppm), further optionally still about 0.025-0.05 wt% (about 250-500 ppm by wt), further optionally about 0.03-0.045 wt% (about 300-450 ppm by wt).
  • the hypochlorite concentration may be 0.035-0.04 wt% (about 350-400 ppm by wt).
  • hypochlorite solutions comprising hypochlorite concentrations below 150 ppm, optionally 200 ppm
  • the reduction in IL-6 function and maintenance of IL-10 function is less effective than concentrations above 150 ppm, optionally 200 ppm.
  • Concentrations of hypochlorite above 150 ppm, optionally 200 ppm have been shown to be particularly effective at reducing IL-6 function, as compared to hypochlorite concentrations of, for instance, less than 150 ppm (e.g. 100 ppm).
  • hypochlorite solutions comprising hypochlorite concentrations 500 ppm or less causes no adverse effects to the cells to which the hypochlorite solution is applied in use (e.g. no evidence of elevated inflammation). It therefore follows that a hypochlorite solution comprising hypochlorite in a concentration range from 150 ppm to 500 ppm, optionally from 200 to 500 ppm, may be particularly advantageous for use in embodiments of the present invention.
  • the hypochlorite solution further comprises sodium chloride.
  • the sodium chloride may be in a concentration range of about 0.2-3.0 wt%, optionally still about 0.3-1.5 wt%, further optionally in a concentration range of about 0.4-1.3 wt%.
  • the inventors have surprisingly discovered that providing a hypochlorite solution in accordance with the present invention, which further comprises sodium chloride, provides unexpected improvement efficacy in reducing IL-6 function, whilst maintaining IL-10 function, as compared to an analogous solution in the absence of sodium chloride (i.e. an aqueous solution comprising hypochlorite).
  • hypochlorite solutions according to the present invention may be unbuffered, providing advantageous modulatory effects on target cytokines implicated in scar tissue formation.
  • the hypochlorite solution for use as described herein may further comprise sodium chloride a concentration range of about 0.5-1 .2%, optionally in a concentration range of about 0.6-1.0% (e.g. 0.7-1.0%), and optionally still in a concentration range of about 0.8- 1.0 wt%.
  • the hypochlorite solution for use as described herein may further comprise 0.8 wt% sodium chloride.
  • the hypochlorite solution for use as described herein may further comprise 0.85 wt% sodium chloride.
  • the hypochlorite solution for use as described herein may further comprise sodium chloride a concentration range of about 0.2-1.0%, optionally at a concentration range of about 0.3-0.8% (e.g. 0.3-0.7%), and optionally still in a concentration range of about 0.3- 0.6 wt% (e.g. 0.3-0.5wt%).
  • the hypochlorite solution for use as described herein may further comprise 0.4 wt% sodium chloride.
  • the hypochlorite solution may be an aqueous sodium hypochlorite solution comprising sodium hypochlorite, sodium chloride, and water to balance.
  • the hypochlorite solution may be an aqueous sodium hypochlorite solution consisting of sodium hypochlorite, sodium chloride, and water to balance.
  • the hypochlorite solution consisting of the foregoing means that other components do not interfere with the function of cytokines involved in the wound healing process and scar tissue formation.
  • the presence of sodium chloride enhances the effect of the hypochlorite solution in modulating the function of cytokines involved in the wound healing process and scar tissue formation, as compared to a hypochlorite solution that does not comprise sodium chloride.
  • only the components of the hypochlorite solution described herein influence cytokine function, and thus advantageously reduce formation of scar tissue.
  • the hypochlorite solution may have a pH of from about 5-11 , preferably about 6-10, more preferably about 7-9, even more preferably about 7-8.
  • the hypochlorite solution may have a pH of from about 7.5-11 (e.g. greater than 7.5 to 11), optionally about 8-10, optionally still about 8.5-9.5, further optionally about 8.5-9 (e.g. pH 9).
  • a hypochlorite solution in accordance with the present invention that has a pH of 7.5 or greater provides unexpected improvement efficacy in reducing IL-6 function, whilst maintaining IL-10 function, as compared to hypochlorite solutions having a lower pH.
  • the hypochlorite solution may comprise less than 0.005 wt% (50 ppm) hypochlorous acid, optionally less than 0.004 wt% (40 ppm) hypochlorous acid, optionally still less than 0.003 wt% (30 ppm), further optionally less than 0.002 (20 ppm).
  • the pH of the hypochlorite solution may be 7.5 or greater, for instance from 7.5-11 , optionally from about 8 to 10, further optionally from about 8.5-9.5 (e.g. about 8.5-9).
  • hypochlorite solutions described herein the equilibrium is to the right in a dynamic equilibrium between HOCI H + + OCI'.
  • concentration of hypochlorous acid ([HOCI]) comprised in the hypochlorite solution relative to the total concentration of hypochlorite ([OCI-]) and hypochlorous acid in the hypochlorite solution may be less than 50 wt%, optionally less than 40 wt%, optionally still less than 30 wt%, further optionally less than 20 wt%, at ambient temperature (i.e. around 20 °C).
  • the concentration of hypochlorous acid ([HOCI]) comprised in the hypochlorite solution relative to the total concentration of hypochlorite ([OCI']) and hypochlorous acid in the hypochlorite solution is less than 10 wt%, preferably still less than 5 wt%, and yet further preferably less than 1 wt% at ambient temperature (i.e. around 20 °C).
  • the pH of the hypochlorite solution may be 7.5 or greater, for instance from 7.5-11 , optionally from about 8 to 10, further optionally from about 8.5-9.5 (e.g. about 9), further optionally still from about 8.5-9.
  • the hypochlorite solution may be substantially free of free chlorine (Ch).
  • the hypochlorite solution may comprise less than 0.0005 wt% (5 ppm) free chlorine (CI2), optionally less than 0.0004 wt% (4 ppm) free chlorine, optionally still less than 0.0003 wt% (3 ppm) free chlorine, further optionally less than 0.0002 wt% (2 ppm) free chlorine (e.g. less than 0.001 wt% [1 ppm]).
  • the pH of the hypochlorite solution may be 5.5 or greater, for instance from 5.5-11 , optionally from about 7.5 to 11.
  • the hypochlorite solution may be unbuffered. That is to say the hypochlorite solution may have an absence of stabilising agents, buffering agents, and the like.
  • the hypochlorite solution being unbuffered means that stabilising agents, buffering agents, and the like to not interfere with the function of cytokines involved in the wound healing process.
  • the components of the hypochlorite solution described herein influence cytokine function, and thus advantageously reduce formation of scar tissue.
  • the hypochlorite solution for use in accordance with the present invention may be unbuffered, have a pH of from about 5-11 (e.g. from 7.5-11 , or from greater than 7.5 to 11), and comprise (or consist of) 0.01-0.2 wt% (e.g. 0.015-0.06 wt%, for instance from 0.02-0.05 wt%) sodium hypochlorite, 0.2-3.0 wt% sodium chloride, and water to balance.
  • concentrations of sodium hypochlorite and sodium chloride may be as defined above in accordance with the first aspect of the present invention.
  • the hypochlorite solution may be unbuffered, and comprise (or consist of) 0.045-0.055 wt% (e.g.
  • hypochlorite solution may be unbuffered, and comprise (or consist of) 0.045-0.055 wt% (e.g. 0.05 wt%) sodium hypochlorite, 0.3-0.5 wt% (e.g. 0.4 wt%) sodium chloride and water to balance.
  • the hypochlorite solution for use in accordance with the present invention may be unbuffered, have a pH of about 9, and comprise (or consist of) 0.015-0.06 wt% (150 to 600 ppm) sodium hypochlorite, from 0.2-3.0 wt% sodium chloride, and water to balance.
  • concentrations of sodium hypochlorite and sodium chloride may be as defined above in accordance with the first aspect of the present invention.
  • hypochlorite solution may be unbuffered, have a pH of about 9, and comprise (or consist of) 0.02-0.05 wt% sodium hypochlorite, 0.8-1.0 wt% (e.g. 0.85 wt% or 0.8 wt%) sodium chloride and water to balance.
  • the hypochlorite solution may be unbuffered, have a pH of about 9, and comprise (or consist of) 0.045-0.055 wt% (e.g. 0.05 wt%) sodium hypochlorite, 0.8-1.0 wt% (e.g. 0.85 wt% or 0.8 wt%) sodium chloride and water to balance.
  • the hypochlorite solution may be unbuffered, have a pH of about 9, and comprise (or consist of) 0.045-0.055 wt% (e.g. 0.05 wt%) sodium hypochlorite, 0.3-0.5 wt% (e.g. 0.4 wt%) sodium chloride and water to balance.
  • hypochlorite solution for use in the prophylactic treatment of scar tissue in a mammal, preferably a human, comprising (or consisting of) 0.045- 0.055 wt% (e.g. 0.05 wt%) sodium hypochlorite, 0.8-1.0 wt% (e.g. 0.85 wt% or 0.8 wt%) sodium chloride and water to balance, optionally wherein the treatment comprises topically administering the hypochlorite solution to an area of the mammal in need thereof at least once daily for a period of at least 30 seconds for at least 14 consecutive days.
  • a hypochlorite solution for use in the prophylactic treatment of scar tissue in a mammal comprising (or consisting of) 0.045- 0.055 wt% (e.g. 0.05 wt%) sodium hypochlorite, 0.8-1.0 wt% (e.g. 0.85 wt% or 0.8 wt%) sodium chloride and water to balance, optionally wherein the treatment comprises administering the hypochlorite solution to the mammal in need thereof at least twice daily, preferably at least three-times daily, preferably still at least four-times daily, for a period of at least 30 minutes for at least 2 consecutive days.
  • a hypochlorite solution for use in the prophylactic treatment of scar tissue in a mammal comprising (or consisting of) 0.045-0.055 wt% (e.g. 0.05 wt%) sodium hypochlorite, 0.3-0.5 wt% (e.g. 0.4 wt%) sodium chloride and water to balance, optionally wherein the treatment comprises topically administering the hypochlorite solution to an area of the mammal in need thereof at least twice a daily, preferably three-times daily, for a period of at least 5 minutes, preferably for a period of at least 30 minutes, for at least 21 consecutive days.
  • compositions for use in the prophylactic treatment of scar tissue in a mammal, more preferably a human wherein the pharmaceutical composition comprises a hypochlorite solution as defined in accordance with the first aspect of the present invention.
  • hypochlorite solution as defined in the first aspect of the present invention in the preparation of a medicament for prophylactic treatment of scar tissue in a mammal, preferably a human.
  • the treatment may be as defined in accordance with the first aspect of the invention.
  • the treatment may be as defined in accordance with the first aspect of the invention.
  • a method for improving the appearance of scar tissue, the method comprising administering an amount of a hypochlorite solution as defined in accordance with the first aspect of the present invention to a mammal, wherein the method is a cosmetic method and the administration is topical administration.
  • a hypochlorite solution for use in the prevention or treatment of scar tissue in a mammal, preferably a human, wherein the hypochlorite solution comprises hypochlorite in a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt; e.g. about 0.015-0.06 wt% [150-600 ppm]).
  • the hypochlorite solution may be as defined in accordance with the first aspect of the invention.
  • the prevention or treatment may be as defined in accordance with the first aspect of the invention.
  • the prevention or treatment of scar tissue may be in the treatment of a wound.
  • the prevention or treatment of scar tissue may be in the prophylactic treatment of disease or condition characterised by abnormal formation of collagen.
  • the prevention or treatment of scar tissue may be in the treatment of purpura fulminans.
  • the treatment may reduce the formation of scar tissue.
  • hypochlorite solution for use in the treatment of purpura fulminans in a mammal, preferably a human, wherein the hypochlorite solution comprises hypochlorite in a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt; e.g. about 0.015-0.06 wt% [150-600 ppm]).
  • the hypochlorite solution may be as defined in accordance with the first aspect of the invention.
  • the treatment may be as defined in accordance with the first aspect of the invention.
  • a hypochlorite solution for use in the prevention or treatment of a disease or condition characterised by the abnormal production of collagen in a mammal, preferably a human, wherein the hypochlorite solution comprises hypochlorite in a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt; e.g. about 0.015-0.06 wt% [150-600 ppm]).
  • the hypochlorite solution may be as defined in accordance with the first aspect of the invention.
  • the treatment may be as defined in accordance with the first aspect of the invention.
  • hypochlorite solution a mammal, preferably a human, in need thereof, wherein the hypochlorite solution is in accordance with the first aspect of the invention.
  • the treatment may be as defined in accordance with the first aspect of the invention.
  • a method of reducing the production of collagen in a fibroblast cell comprising contacting the cell with a hypochlorite solution comprising hypochlorite in a concentration range of about 0.01- 0.2 wt% (about 100-2000 ppm by wt; e.g. about 0.015-0.06 wt% [150-600 ppm]) for a period of time sufficient to decrease activity of interleukin-6 (IL-6) and to maintain activity of inerleukin-10 (IL-10).
  • the method is preferably not a method of treatment practised on the human or animal body (e.g. is an in vitro or ex vivo method).
  • hypochlorite solution administered to a mammal, preferably a human, in need thereof, wherein the hypochlorite solution is in accordance with the first aspect of the invention.
  • the treatment may be as defined in accordance with the first aspect of the invention.
  • a method of controlling differentiation of a fibroblast cell comprising contacting the cell with a hypochlorite solution comprising hypochlorite in a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt; e.g. about 0.015-0.06 wt% [150-600 ppm]) for a period of time sufficient to decrease activity of interleukin-6 (IL-6) and to maintain activity of inerleukin-10 (IL-10).
  • the method is preferably not a method of treatment practised on the human or animal body (e.g. is an in vitro or ex vivo method).
  • hypochlorite solution administered to a mammal, preferably a human, in need thereof, wherein the hypochlorite solution is in accordance with the first aspect of the invention.
  • the treatment may be as defined in accordance with the first aspect of the invention.
  • Figure 1 shows IL-6 cells in Example 1 dialysed against a control saline solution (0.85 wt%) to determine functionality of cytokine.
  • Figure 2 shows IL-6 cells in Example 1 dialysed against a solution of Composition 1 to determine functionality of cytokine.
  • Figure 3 shows IL-6 cells in Example 1 dialysed against a solution of Composition 2 to determine functionality of cytokine.
  • Figure 4 shows IL-10 cells in Example 2 dialysed against a control saline solution (0.85 wt%) to determine functionality of cytokine.
  • Figure 5 shows IL-10 cells in Example 2 dialysed against a solution of Composition 1 to determine functionality of cytokine.
  • Figure 6 shows IL-10 cells in Example 2 dialysed against a solution of Composition 2 to determine functionality of cytokine.
  • Figure 7 shows survival of MC9 cells following exposure of IL-10 to A (Composition 1) and B (Composition 2).
  • Figure 8 shows survival of B9 cells following exposure of IL-6 to A (Composition 1) and B (Composition 2).
  • Figure 9 is a photograph of the ankle area of the patient according to Example 5.
  • Figure 10 are photographs of the outside left thigh of the patient according to Example 8.
  • Figure 10A was taken before treatment
  • Figure 10B was taken during treatment
  • Figure 10C was taken after 14 days of treatment.
  • treating means reversing, attenuating, alleviating or inhibiting the progress of the disease or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • prophylactic treatment means treatment designed to prevent the condition from occurring or minimize the likelihood of a condition occurring.
  • the prophylactic treatment of scar tissue encompasses the prevention of the formation of scar tissue as well as reduction (e.g. in surface area and/or level of severity) of the formation of scar tissue.
  • scar tissue refers to tissue which is formed during the wound healing process or as a result of a disease or condition that causes scarring of normal tissue. Scar tissue forms as a direct consequence of trauma to normal tissue e.g. the skin. Fibrosis is the process by which new tissue is formed in response to a wound, leading to tissue remodeling and the formation of scar tissue. Fibrosis may therefore be used in the art to mean the process by which scar tissue is formed. Fibrosis is facilitated by fibroblast cells. As such, wherever prophylactic treatment of scar tissue or treatment of scar tissue is referred to herein, those skilled in the art will understand that prevention or treatment of fibrosis is also contemplated.
  • a disease or condition characterised by the abnormal formation of collagen may be any disease or condition which causes scarring to tissue.
  • diseases and conditions may be selected from myocardial fibrosis and purpura fulminans.
  • diseases and conditions may include pulmonary fibrosis, chronic obstructive pulmonary disease, and long COVID-19.
  • open wound refers to an injury of the skin, wherein the skin is punctured, torn or cut, and exposes internal body tissue.
  • the term encompasses incisions, lacerations, abrasions, punctures, and gunshots.
  • the term refers to the wound before it is closed by natural healing processes.
  • “Patient” includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
  • non-human mammals e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like
  • non-mammals e.g., birds, and the like.
  • wt% refers to the weight by mass relative to the total weight of the hypochlorite solution.
  • hypochlorite solution of the present invention acts on the known initiators, mediators and regulators of scar tissue formation.
  • the solution of the invention is thought to inhibit the release of inflammatory agents (e.g. cytokines and chemokines) from blood platelets, but does not prevent the platelets from aggregating. It is thought that the solution also attenuates the effect of cytokines, chemokines and other inflammatory mediators. Proof of concept that such an effect can be exploited in the prophylactic treatment scar tissue has been demonstrated in the Examples described herein. It has also been found that such an effect can be provided without serious safety issues, as demonstrated in the Examples described herein.
  • inflammatory agents e.g. cytokines and chemokines
  • hypochlorite solution as described herein can selectively affect the function of particular antiinflammatory cytokines.
  • the data described herein demonstrates that the hypochlorite solution as described herein causes loss of IL-6 function in vitro. Conversely, the hypochlorite solution as described herein led to no significant change in IL-10 function in vitro.
  • the hypochlorite solution of the present invention can disrupt normal cytokine activity in vitro thus providing a means of controlling cytokine-dependent cell signalling pathways.
  • IL-6 has been implicated in promoting formation of scar tissue and fibrosis (Johnson et a/; DOI: 10.3390/biomedicines8050101).
  • IL-10 has been implicated in regulation of fibrogenic cytokines, the extracellular matrix, and promotion of fibroblast function. IL-10 has therefore been shown to have a role in tissue remodelling and reducing scar formation (King et al DOI 10.1089/wound.2013.0461).
  • these data indicate that use of the hypochlorite solution according to the present invention causes loss of IL-6 function whilst maintaining IL-10 function, which signals a net negative effect on scar tissue formation.
  • hypochlorite (OCT) solutions are eminently suitable at the concentrations described.
  • the hypochlorite solution described herein does not comprise chlorite (CIO2').
  • the hypochlorite solution for use as described herein may be administered topically to an area of the mammal in need thereof (e.g. tissue that is the site of trauma).
  • the hypochlorite solution may be provided as a solution and topically applied by means of irrigating, submerging or washing the tissue to be treated (e.g. a wound) in the hypochlorite solution for a period of time.
  • the hypochlorite solution may be provided in the form of a cream or gel, and applied directly to the tissue to be treated (e.g. a wound).
  • the hypochlorite solution may be topically administered for a period of about 30 seconds to about 90 minutes.
  • the hypochlorite solution is topically administered 1 minute to about 90 minutes, about 5 minutes to about 90 minutes, about 10 minutes to about 90 minutes, about 15 minutes to about 90 minutes, about 20 minutes to about 90 minutes, about 30 minutes to about 90 minutes, about 45 minutes to about 90 minutes, about 60 minutes to about 90 minutes, about 30 seconds to about 60 minutes, about 30 seconds to about 45 minutes, about 30 seconds to about 30 minutes, about 30 seconds to about 20 minutes, about 30 seconds to about 15 minutes, about 30 seconds to about 10 minutes, about 30 seconds to about 5 minutes or about 30 seconds to about 1 minute.
  • the hypochlorite solution may be topically administered for at least 5 minutes, optionally at least 10 minutes, optionally still at least 15 minutes.
  • the tissue to be treated e.g. a wound
  • the tissue to be treated may be irrigated with, submerged in, or washed with the hypochlorite solution for at least 20 minutes, optionally at least 30 minutes.
  • the hypochlorite solution for use as described herein may be administered topically at least once daily.
  • the prophylactic treatment may comprise topical administration of the hypochlorite solution at least twice daily, optionally at least three- times daily, and optionally still at least four times daily.
  • the hypochlorite solution may be administered topically for 2 to 30 consecutive days, optionally for 5 to 28 consecutive days, optionally still from 7 to 14 consecutive days.
  • the treatment may comprise topical administration of the hypochlorite solution on alternate days, for a period of 2 to 30 consecutive days, optionally 5 to 28 consecutive days, optionally still 7 to 14 consecutive days.
  • hypochlorite solution is topically administered for at least 5 consecutive days at least once daily, optionally at least 7 consecutive days at least once daily, and optionally still at least 14 consecutive days at least once daily (e.g. twice daily).
  • the hypochlorite solution for use as described herein may be administered by inhalation e.g. via a nebulizer.
  • the type of nebulizer is not particularly limited provided that it is able to break up the hypochlorite solution into aerosol droplets for inhalation.
  • the nebulizer may be connected to an outlet configured to deliver the hypochlorite solution to a patient via the nose and/or mouth.
  • the outlet may be a mouthpiece or a facemask.
  • the hypochlorite solution for use as described herein may be administered by inhalation e.g. via an inhaler.
  • the inhaler may be a metered-dose inhaler.
  • the metered-dose inhaler may be configured to deliver a set dose of the hypochlorite solution on each actuation of the metered-dose inhaler.
  • the hypochlorite solution for use as described herein may be provided in a medicament container that is suitable for use with an inhalation device.
  • Medicament containers may include cartridges or canisters suitable for use with inhalation devices such as an inhaler or nebuliser.
  • the hypochlorite solution for use as described herein may be packaged into a cartridge containing a propellant, thus forming a cartridge comprising a hypochlorite solution and a propellant.
  • hypochlorite solution may be packaged into a canister container a propellant, thus forming a canister comprising a hypochlorite solution and a propellant.
  • the propellant may be a chlorofluorocarbon or a hydrofluoroalkane, or the like.
  • the cartridge or canister may be used with an inhaler. The cartridge or canister may be detachable from the inhaler. The cartridge or canister may be attached to the inhaler prior to use.
  • the hypochlorite solution may be administered via inhalation continuously.
  • continuous administration via inhalation may be applied to ventilated patients, patients in a hospital setting, sedated patients, or patients in a coma or induced coma.
  • the administration may be for a period of about 30 seconds to about 90 minutes.
  • the hypochlorite solution is administered via inhalation for a period of about 1 minute to about 90 minutes, about 5 minutes to about 90 minutes, about 10 minutes to about 90 minutes, about 15 minutes to about 90 minutes, about 20 minutes to about 90 minutes, about 30 minutes to about 90 minutes, about 45 minutes to about 90 minutes, about 60 minutes to about 90 minutes, about 30 seconds to about 60 minutes, about 30 seconds to about 45 minutes, about 30 seconds to about 30 minutes, about 30 seconds to about 20 minutes, about 30 seconds to about 15 minutes, about 30 seconds to about 10 minutes, about 30 seconds to about 5 minutes or about 30 seconds to about 1 minute.
  • the hypochlorite solution may be administered via inhalation once, twice, thrice or four times daily.
  • the hypochlorite solution is administered once daily.
  • the hypochlorite solution may be administered in a cycle comprising a treatment period of administration of the hypochlorite solution once, twice, thrice or four times daily for a period of a few days (e.g. about 1 , 2, 3, 4, 5, 6 or 7 days) to a few weeks (e.g. about 1 , 2, 3 or 4 weeks), optionally followed by a period where the hypochlorite solution is not administered for a period of a few days (e.g. about 1 , 2, 3, 4, 5, 6 or 7 days) to a few weeks (e.g. about 1 , 2, 3 or 4 weeks).
  • the cycle may be repeated at least twice. For example, the cycle may be repeated twice, thrice, four times, five times, six times, seven times, eight times, nine times, ten times, etc.
  • hypochlorite solution for use as described herein is preferably an aqueous solution.
  • the hypochlorite solution contains hypochlorite in a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt), more preferably about 0.01-0.1 wt% (about 100-1000 ppm by wt), even more preferably about 0.015-0.075 wt% (about 150- 750 ppm), yet even more preferably about 0.025-0.075 wt% (about 250-750 ppm by wt), most preferably about 0.04-0.06 wt% (about 400-600 ppm by wt).
  • the hypochlorite solution contains hypochlorite at about 0.05 wt% (about 500 ppm by wt).
  • the hypochlorite solution for use as described herein may further comprise sodium chloride, optionally in a concentration range of about 0.2-3.0 wt%, optionally still about 0.3-1.5 wt%, further optionally in a concentration range of about 0.4-1.3 wt%.
  • the hypochlorite solution for use as described herein may further comprise sodium chloride a concentration range of about 0.5-1 .2%, optionally in a concentration range of about 0.6-1.0% (e.g. 0.7-1 .0%), and further optionally in a concentration range of about 0.8-1.0 wt% (e.g. 0.8-0.9 wt%).
  • the hypochlorite solution for use as described herein may further comprise 0.85 wt% sodium chloride.
  • the hypochlorite solution for use as described herein may further comprise sodium chloride a concentration range of about 0.2-1.0%, optionally in a concentration range of about 0.3-0.8% (e.g. 0.3-0.7%), and optionally still in a concentration range of about 0.3-0.6 wt% (e.g. 0.3-0.5wt%).
  • the hypochlorite solution for use as described herein may further comprise 0.4 wt% sodium chloride.
  • the hypochlorite solution for use as described herein may have a pH of from about 5- 11 , preferably about 6-10, more preferably about 7-9, even more preferably about 7-8. In some embodiments, the pH may be about 5-6, about 6-7, about 8-9, about 9-10, or about 10-11. In embodiments, the pH of the hypochlorite solution is greater than 7.5 or the pH of the hypochlorite solution is 7.5 or greater. For example, in embodiments, the pH of the hypochlorite solution is from 10-11. Alkaline pHs are generally preferred to ensure the presence of hypochlorite ion (CIO-). Acidification of hypochlorites generates hypochlorous acid which is a different chemical entity.
  • CIO- hypochlorite ion
  • the hypochlorite solution for use as described herein may have a pH of from about 7.5- 11 , optionally from greater than 7.5 to about 11 , optionally still about 8-10, further optionally about 8.5-9.5 (e.g. about pH 9), further optionally still about 8.5-9.
  • the pH of the hypochlorite solution is within a range encountered in normal physiology and disease processes. This is because the hypochlorite solution preferably auto-adjusts pH.
  • the hypochlorite solution described herein is preferably unbuffered as described in more detail below, and so when the hypochlorite solution described herein is applied to a patient in need thereof (e.g. to an area of the skin), the pH of the hypochlorite solution adjusts to the pH of the area of application.
  • hypochlorite solution for use as described herein may be unbuffered.
  • the hypochlorite solution is unbuffered.
  • the hypochlorite solution is free of buffer agents.
  • the hypochlorite solution is preferably free of stabilising agents.
  • the hypochlorite solution is therefore free of other agents which may otherwise disrupt the beneficial effects described herein on IL-6 and IL-10 activity.
  • Beneficial effects for the prevention or treatment of scar tissue are particularly noticeable where the patient is treated with a solution which has a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt), yet more preferably about 0.01-0.1 wt% (about 100-1000 ppm by wt), even more preferably about 0.025-0.075 wt% (about 250- 750 ppm by wt) sodium hypochlorite; sodium chloride in a concentration range of about 0.3-1 .5 wt%, optionally in a concentration range of about 0.4-1.3 wt%, optionally still in a concentration range of about 0.5-1.2%, further optionally in a concentration range of about 0.8-1.0 wt%; wherein the solution is unbuffered.
  • the solution consists of about 0.01-0.2 wt% (about 100-2000 ppm by wt), yet more preferably about 0.01-0.1 wt% (about 100-1000 ppm by wt), even more preferably about 0.025-0.075 wt% (about 250-750 ppm by wt) sodium hypochlorite; sodium chloride in a concentration range of about 0.3-1.5 wt%, optionally in a concentration range of about 0.4-1.3 wt%, optionally still in a concentration range of about 0.5-1 .2%, further optionally in a concentration range of about 0.8-1 .0 wt%; wherein the solution is unbuffered.
  • beneficial effects for the prevention or treatment of scar tissue are particularly noticeable where the patient is treated with a solution which has a concentration range of about 0.015-0.06 wt% (about 150-600 ppm by wt), yet more preferably about 0.02-0.5 wt% (about 200-500 ppm by wt), even more preferably about 0.025-0.045 wt% (about 250-450 ppm by wt) sodium hypochlorite; sodium chloride in a concentration range of about 0.3-1.5 wt%, optionally in a concentration range of about 0.4-1.3 wt%, optionally still in a concentration range of about 0.5-1.2%, further optionally in a concentration range of about 0.8-1.0 wt%; wherein the solution is unbuffered, and has a pH of 7.5 or greater.
  • Beneficial effects for the prevention or treatment of scar tissue are particularly noticeable where the patient is treated with a solution which has a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt), yet more preferably about 0.01-0.1 wt% (about 100-1000 ppm by wt), even more preferably about 0.025-0.075 wt% (about 250- 750 ppm by wt) sodium hypochlorite; sodium chloride in a concentration range of about 0.3-1 .5 wt%, optionally in a concentration range of about 0.4-1.3 wt%, optionally still in a concentration range of about 0.5-1.2%, further optionally in a concentration range of about 0.8-1.0 wt%; wherein the solution is buffered to a pH of from about 5-11 , preferably about 6-10.
  • hypochlorite solution comprising 0.85% sodium chloride and 0.05% (500 ppm) sodium hypochlorite w/w has been found to be very beneficial in preventing and treating scar tissue in a patient, preferably a mammal, more preferably a human.
  • hypochlorite solution comprising 0.4% sodium chloride and 0.05% (500 ppm) sodium hypochlorite w/w has been found to be very beneficial in preventing and treating scar tissue in a patient, preferably a mammal, more preferably a human.
  • the hypochlorite solution should be very pure.
  • the hypochlorite solution is generated electrolytically to ensure its purity as well as its safety and effectiveness.
  • the hypochlorite solution comprises hypochlorite (e.g. sodium hypochlorite), water, and optionally sodium chloride in a purity of greater than 90 %, optionally greater than 95 wt%, optionally still greater than 98 wt%, further optionally greater than 99 wt%, relative to the total weight of the hypochlorite solution.
  • the hypochlorite solution may be produced from a concentrated hypochlorite solution to be diluted before use.
  • the concentrated hypochlorite solution to be diluted before use is a concentrated sodium hypochlorite solution.
  • the concentration of hypochlorite in the concentrated hypochlorite solution may be in the range of about 0.5 to 3 wt%.
  • the concentrated hypochlorite solution may be buffered to a pH of from about 9-15, preferably about 11-13.
  • the concentrated hypochlorite solution may be unbuffered.
  • the concentrated hypochlorite solution may be a stabilised sodium hypochlorite solution at 1% or 2% sodium hypochlorite, e.g.
  • the diluted hypochlorite solution may be a 2.5% - 10% solution of Milton’s solution diluted in water where the disinfectant solution is 2% sodium hypochlorite.
  • the sodium chloride in the solution is typically at a concentration of 16.5%.
  • the ratio by volume of the hypochlorite solution to water may be in the range of from 1 to 10 to 1 to 40.
  • the dilute hypochlorite solution may be a 5% to 20% solution of Milton’s solution diluted in water where the disinfectant solution is 1% sodium hypochlorite.
  • the ratio by volume of the hypochlorite solution to water may be in the range of from 1 to 5 to 1 to 20.
  • the predetermined amount of water and the predetermined amount of sodium hypochlorite solution may be such that the dilute disinfectant solution may be a stabilised sodium hypochlorite solution where the sodium hypochlorite is in a concentration range of about 0.01-0.2 wt% (about 100-2000 ppm by wt), more preferably about 0.01-0.1 wt% (about 100-1000 ppm by wt), even more preferably about 0.025- 0.075 wt% (about 250-750 ppm by wt) sodium hypochlorite.
  • the action of the sodium hypochlorite solution can provide stabilisation of the dilute disinfectant solution.
  • a device suitable for preparing a hypochlorite solution for use in the present invention is described in WO-A-2011/128862.
  • IL-10 Dependent cell line MC9 (ARCC ® CRL-8306TM, Mouse liver mast cell)
  • PrestoBlue® cell-permeable fluorescent compound for use in cell-viability assays
  • Plasma samples were obtained from a volunteer and the cells were separated from the plasma.
  • the plasma samples were placed in dialysis tubing whose pore size was less than the molecular weight of the cytokines. This was placed in 1000x excess (i.e. 1 ml in 1 L, 2 ml in 2 L etc.) of dialysis media.
  • the dialysis media was in either saline solution (0.85 wt%) as a control, Composition 1 or Composition 2 and was extracted after 5 minutes, 15 minutes, 30 minutes, 45 minutes and 60 minutes and then analysed. The cytokine functionality was thus determined.
  • Cytokine Function Functional cell assays were carried out with patient plasma to investigate its ability to support the survival of cytokine dependent cell lines.
  • the serum was spiked with human recombinant cytokines. Heat-inactivated fetal bovine serum was used and was spiked with human recombinant IL-6 and IL-10 at 100 ng/ml.
  • the serum samples were dialysed with either 0.85 wt% saline solution, Composition 1 or Composition 2, as described above.
  • IL-6 function was assessed by determining the ability to maintain the growth of the IL-6 dependent cell line B9.
  • IL-10 Function was assessed by the ability to maintain the growth of the IL-10 dependent cell line MC9.
  • Cell viability was measured using fluorescence. A cell-permeable non-fluorescent compound was added to the assay. Viable cells maintain a reducing environment, which reduced the fluorescent compound, giving a colour change which fluoresces at 560 nm.
  • a high level of cytokine i.e. 10ng/ml
  • cytokine caused a decrease in cell viability.
  • the inventors postulate that this may be due to a prozone-like effect at high cytokine levels and/or that high levels of cytokine may cause cell death or the inhibition of cell metabolism in this system.
  • Figures 1 to 3 show the results from the cell-survival assay of the IL-6 spiked-serum samples dialysed against a control saline solution ( Figure 1), Composition 1 ( Figure 2) and Composition 2 ( Figure 3).
  • Figures 2 and 3 show that dialysis of the serum samples with Composition 1 or Composition 2 of the present invention and leads to a loss of function of the IL-6 molecule when measured in the cell survival assay.
  • Figures 4 to 6 show the results from the cell survival assay of the IL-10 spiked-serum samples dialysed against a control saline solution ( Figure 4), Composition 1 ( Figure 5) and Composition 2 ( Figure 6).
  • IL-6 may act as a pro- inflammatory and pro-fibrosis agent in opposition to the anti-inflammatory and antifibrosis action of IL-10. Loss of IL-6 function therefore (at least partially) attenuates IL- 6’s opposing effect on IL-10 function and IL-10’s associated downstream effects.
  • the ratio of IL-6 and IL-10, or increase in relative levels of IL-10 may therefore predict the likelihood of scar tissue formation. For instance, King et al (Advances in Wound Care, Vol. 3, No.4, p.315) that IL-10 has been associated with wound healing and reduced scar formation. Additionally, Xi et al (2017 PLoS 2017 12(6)) describes that IL-10 may be used as a marker for predicting clinical outcome in patients with sepsis-induced immunosuppression.
  • hypochlorite solutions according to the present invention may assist in scar prophylaxis by promoting IL-10 function and reducing IL-6 function, thereby attenuating or removing the mitigating effects of IL-6 on IL-10 function.
  • Treatment comprised topical administration of aqueous sodium hypochlorite solution in saline (NaOCI: 0.05 wt% (500 ppm), NaCI: 0.85 wt%) daily for 14 consecutive days. Gauze was soaked in the aqueous sodium hypochlorite solution and placed on the lacerations. Facial lacerations fully healed within four weeks without any evidence of scar tissue or skin discoloration.
  • Treatment comprised topical administration of aqueous sodium hypochlorite solution in saline (NaOCI: 0.05 wt% (500 ppm), NaCI: 0.85 wt%) daily for 14 consecutive days.
  • the aqueous sodium hypochlorite solution was used as a mouth wash daily. Mouth ulcers fully healed within four weeks without any evidence of scar tissue or tissue discoloration.
  • Treatment comprised topical administration of aqueous sodium hypochlorite solution in saline (NaOCI: 0.05 wt% (500 ppm), NaCI: 0.85 wt%) daily for 14 consecutive days.
  • the aqueous sodium hypochlorite solution was used as a mouth wash daily.
  • Patient reported alleviation of symptoms, improved healing, and additionally ceased to take painkillers within 1 week of starting treatment.
  • the intra-oral trauma sites fully healed within four weeks without any evidence of scar tissue or tissue discoloration.
  • Treatment comprised administration of aqueous sodium hypochlorite solution in saline (NaOCI: 0.05 wt% (500 ppm), NaCI: 0.85 wt% - referred to in Example 7 as Composition 3), delivered by nebulizer.
  • NaOCI 0.05 wt% (500 ppm)
  • NaCI 0.85 wt% - referred to in Example 7 as Composition 3
  • composition 3 was administered to each patient by nebuliserforthe time periods indicated in the table below. Frequency of inhalation is indicated as (number of times per day x duration of each treatment session). Where administration was 4 times daily, Composition 3 was administered every 6 hours. Where administration was 3 times daily, Composition 3 was administered every 8 hours. For patients 1-4, the treatment was administered at the indicated frequency on consecutive days until the patient reported no symptoms. Treatment was administered at the indicated frequency for 21 consecutive days for patient 5, and for 7 consecutive days for patient 6.
  • composition 3 administered via inhalation is an effective treatment for symptoms of long COVID-19.
  • patients who suffer with long COVID-19 for extended periods e.g. longer than 6 months
  • Composition 3 prevents significant scarring to the lungs.
  • significant scarring has already occurred (i.e. treating patients 12 months or more from the date of a positive COVID-19 test)
  • Composition 3 is less effective in treating long COVID-19, but may still provide some therapeutic benefit.
  • this partial therapeutic benefit may arise from reducing scar tissue in the lungs of the patient.
  • Female. 1 st Decade Patient admitted to hospital with varicella-associated purpura fulminans, a rare condition associated with a high mortality, amputations and scarring to tissue.
  • the patient developed large purpuric skin lesions, which may become necrotic lesions, following admission to hospital.
  • Treatment comprised bathing the patient in an aqueous sodium hypochlorite solution according to composition 3 (NaOCI: 0.05 wt% (500 ppm), NaCI: 0.4 wt %) three-times daily (every 8 hours) for 30 minutes each time. Treatment was carried outfor21 consecutive days.
  • the purpuric skin lesions healed fully without any remaining indication of scarring.
  • the patient made a full recovery without any scarring to the tissue.
  • Figures 10A-10C are images of a large purpuric skin lesion on the patient’s upper left leg.
  • Figure 10A shows the lesion before treatment
  • Figure 10B shows the lesion during treatment
  • Figure 10C shows the lesion after 14 days of treatment. At 21 days, the lesions had fully healed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Birds (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une solution d'hypochlorite destinée à être utilisée dans le traitement prophylactique de tissu cicatriciel chez un mammifère, de préférence un être humain, la solution d'hypochlorite comprenant de l'hypochlorite dans une plage de concentration d'environ 0,015 à 0,06 % en poids (environ 150 à 600 ppm en poids), la solution d'hypochlorite ayant un pH égal ou supérieur à 7,5 et la solution d'hypochlorite comprenant en outre de 0,2 à 3,0 % en poids de chlorure de sodium.
EP23809512.9A 2022-11-17 2023-11-16 Solution d'hypochlorite pour le traitement de tissu cicatriciel Pending EP4619008A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2217192.0A GB2624421A (en) 2022-11-17 2022-11-17 Scar tissue prophylaxis
PCT/EP2023/082101 WO2024105186A1 (fr) 2022-11-17 2023-11-16 Solution d'hypochlorite pour le traitement de tissu cicatriciel

Publications (1)

Publication Number Publication Date
EP4619008A1 true EP4619008A1 (fr) 2025-09-24

Family

ID=84889159

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23809512.9A Pending EP4619008A1 (fr) 2022-11-17 2023-11-16 Solution d'hypochlorite pour le traitement de tissu cicatriciel

Country Status (6)

Country Link
EP (1) EP4619008A1 (fr)
JP (1) JP2025537830A (fr)
KR (1) KR20250108665A (fr)
AU (1) AU2023381281A1 (fr)
GB (1) GB2624421A (fr)
WO (1) WO2024105186A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411021A4 (fr) * 2009-03-23 2012-09-05 Kross Link Lab Méthode de suppression ou de prévention de la formation d'adhésions fibreuses utilisant une composition d'oxychlorine aqueuse à plusieurs composants préparée sur site
SG184886A1 (en) 2010-04-14 2012-11-29 Discovery Holdings Ltd A method of managing a driver rewards programme and a system therefor
CA2924059C (fr) * 2013-09-11 2022-01-04 Glenn Abrahmsohn Compositions therapeutiques et fabrication et utilisation associees
GB2519774A (en) 2013-10-29 2015-05-06 Hypo Stream Ltd Anti-inflammatory solution
GB2527264A (en) 2014-01-23 2015-12-23 Hypo Stream Ltd Anti-inflammatory solution
WO2022038507A1 (fr) * 2020-08-17 2022-02-24 Jacobus Johannes Viljoen Solution destinée à être utilisée dans le traitement de l'hypoxémie et d'une asphyxie potentielle
GB2599795A (en) * 2020-09-15 2022-04-13 Facerestoration Ltd Lavage techniques and virucidal compositions comprising hypochlorous solutions

Also Published As

Publication number Publication date
GB2624421A (en) 2024-05-22
KR20250108665A (ko) 2025-07-15
WO2024105186A1 (fr) 2024-05-23
JP2025537830A (ja) 2025-11-20
GB202217192D0 (en) 2023-01-04
AU2023381281A1 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
EP1307189B1 (fr) Utilisation d'hydroxyethylrutosides pour traiter les symptomes du rhume, la rhinite allergique et les infections liees aux voies respiratoires
AU2001279587A1 (en) Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
US20090182055A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
KR20170018852A (ko) 상처 치료를 위한 국소 조성물 및 방법
WO2008026310A1 (fr) Agent protecteur pour une muqueuse orale contenant du tréhalose
WO2019040185A1 (fr) Miel de sarrasin et pansement de cicatrisation pour plaie à base de povidone iodée
RU2667653C1 (ru) Способ лечения воспалительных заболеваний слизистых оболочек с помощью порошкообразной формы тромбоцитарной аутологичной плазмы
Huang et al. Aquacel® Ag with Vaseline gauze in the management of toxic epidermal necrolysis (TEN)
RU2229864C1 (ru) Способ лечения инфекционных язв и кератитов
EP4619008A1 (fr) Solution d'hypochlorite pour le traitement de tissu cicatriciel
RU2394567C1 (ru) Способ лечения хронических фарингитов раствором новокаина и мексидола
RU2757360C1 (ru) Применение фосфолипидной эмульсии, содержащей эффективное количество дигидрокверцетина, лецитин и глицин для лечения воспалительных заболеваний органов дыхания
Barnikol et al. Complete healing of chronic wounds of a lower leg with haemoglobin spray and regeneration of an accompanying severe dermatoliposclerosis with intermittent normobaric oxygen inhalation (INBOI): a case report
RU2528905C1 (ru) Способ лечения ран мягких тканей различной этиологии
CN108635362B (zh) 一种治疗糖尿病足的药物组合物
RU2082405C1 (ru) Средство "хлорфиз" для лечения ринита
RU2833400C1 (ru) Способ лечения гнойно-очаговых заболеваний кожи озонотерапией
Archer Upper airways obstruction after Dettol ingestion
RU2326658C1 (ru) Способ ведения послеоперационной раны на пародонте
RU2460528C2 (ru) Способ местной иммунотерапии хронического одонтогенного верхнечелюстного синусита
RU2797957C1 (ru) Антисептическая комбинация, антисептическая фармацевтическая композиция и их применение
CAMPBELL et al. FRESH COMPOUND FRACTURES: TREATMENT BY SULFONAMIDES AND BY INTERNAL FIXATION IN SELECTED CASES
Abdellatife EFFICACY OF OZONE GEL, DOXYCYCLINE SATURATED CHITOSAN DRESSING VERSUS ALVEOGYL IN PAIN ALLEVIATION AND HEALING OF ALVEOLAR OSTEITIS IN DIABETIC PATIENTS DOUBLE BLIND RANDOMIZED CLINICAL TRAIL
EP4520338A1 (fr) Composition pharmaceutique homéopathique pour le traitement de maladies des voies respiratoires supérieures et inférieures
Maquert How quickly can haemoglobin A, increase?

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR